Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
UNLABELLED: (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00221.x, 2012) Aims/Introduction: To determine the efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients after 3 months' therapy. MATERIALS AND METHODS: A retrospective, observational study of 741 type 2 diabetes patients was carried out; 110 received sitagliptin monotherapy, and 631 received combination therapy with sitagliptin when other oral medications were insufficient. The primary outcome measure was glycated hemoglobin (HbA1c) measured at 0, 4 and 12 weeks of sitagliptin therapy. RESULTS: In the monotherapy and combination therapy groups, HbA1c decreased significantly after 12 weeks. Target HbA1c (<7%) was achieved in 39.1% overall. On logistic regression analysis, baseline HbA1c was the strongest contributing factor for achieving target HbA1c; baseline body mass index and duration of diabetes were also significant factors. A total of 82 patients (11%) were unresponsive to sitagliptin. These patients' baseline body mass index was significantly higher and their baseline HbA1c was significantly lower than those of patients who responded to sitagliptin. The most commonly co-administered drugs were sulfonylureas (508 patients). In these patients, the dose of sulfonylurea decreased with time. In 66 patients whose sulfonylurea dosage was reduced when sitagliptin was started, HbA1c and bodyweight decreased significantly after 12 weeks. A total of 24 patients receiving sulfonylureas had mild hypoglycemia, but none discontinued sitagliptin. CONCLUSIONS: Sitagliptin was effective and safe as both monotherapy and combination therapy in Japanese type 2 diabetes patients. When sulfonylureas were ineffective, sitagliptin improved glycemic control. In patients whose sulfonylurea dose was reduced at the start of sitagliptin, blood glucose improved and bodyweight decreased after 12 weeks.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
- Date Crossref
- 26/06/2012
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kanagawa Prefecture Medical Association pays non établi dans la noticeInstitution
-
St. Marianna University School of Medicine Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Yokohama City University Medical Center Department of Endocrinology and Diabetes pays non établi dans la noticeÉtablissement de santé
-
Yokohama City University pays non établi dans la noticeUniversité ou école supérieure
-
Kanagawa Physicians Association The Study Group of the Diabetes Committee pays non établi dans la noticeOrganisation à but non lucratif
-
St Marianna University School of Medicine Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
Kanagawa Prefecture Medical Association, Department of Internal Medicine — St. Marianna University School of Medicine et Department of Endocrinology and Diabetes — Yokohama City University Medical Center, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.